In this podcast by Healio, host Shikha Jain, MD, FACP, covers modern day health care in an ever-evolving world. Through interviews with experts, Jain explores hot topics in oncology and beyond.
Oncology Overdrive
Claim This Podcastby Shikha Jain, MD
4.9(15 reviews)
138 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
42
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality49
Social0
YouTube0
Engagement85
Podcast Overview
In this podcast by Healio, host Shikha Jain, MD, FACP, covers modern day health care in an ever-evolving world. Through interviews with experts, Jain explores hot topics in oncology and beyond.
Language
🇺🇲
Publishing Since
5/8/2020
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
42
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality49
Social0
YouTube0
Engagement85
6
Excellent Areas
1
Good Performance
12
Growth Opportunities
excellent
Episode Length
41 minutes
Performing excellently!
good
iTunes Tags
7.2/10
Recommendations available
Unlock the full report to see detailed tips
needs improvement
Publishing Consistency
Every 16 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Oncology Overdrive
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 9, 2026
Live from ASCO 2026: Women in oncology on the importance of building relationships
<p class="BodyCxSpFirst"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> In this episode, recorded live at ASCO Annual Meeting, host</span> <strong style="mso-bidi-font-weight: normal;"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"> Shikha Jain, MD,</span></strong> <span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> speaks with</span> <strong style= "mso-bidi-font-weight: normal;"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"> Erin Gillaspie, MD, MPH,</span></strong> <span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> and</span> <strong style= "mso-bidi-font-weight: normal;"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"> Laurie Matt-Amaral, MD, MPH,</span></strong> <span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> about navigating challenges as women in oncology, investing in relationships and more.<br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">Gillaspie and Matt-Amaral share their journeys within their fields. <strong>2:37<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">Have you ever experienced imposter syndrome?</span> <strong style= "mso-bidi-font-weight: normal;">9:26</strong><span style= "mso-bidi-font-weight: bold;"><br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">How did you navigate moments when it felt like you had hit a wall? <strong>10:36<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">How have you balanced family life and your career?</span> <strong style= "mso-bidi-font-weight: normal;">21:25<span style= "mso-bidi-font-weight: bold;"><br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></span></strong></p> <p class="BodyCxSpLast" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->If you had to give two or three tips for up-and-coming women physicians, what would they be? <strong>30:07<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></p> <p class="HealioSubhead"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> We'd love to hear from you! Send your comments/questions to Jain at</span> <a href= "mailto:oncologyoverdrive@healio.com"><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> oncologyoverdrive@healio.com</span></a><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">. Follow Healio on X and LinkedIn:</span> <a href= "https://twitter.com/HemOncToday"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> @HemOncToday</span></a> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> and</span> <a href= "https://www.linkedin.com/company/hemonctoday/"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> https://www.linkedin.com/company/hemonctoday/</span></a><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">. Follow Jain on X:</span> <a href= "https://x.com/ShikhaJainMD"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> @ShikhaJainMD</span></a> <span style= "font-size: 12.0pt; line-height: 115%;">and on Instagram</span> <a href="https://www.instagram.com/shikhajainmd/"><span style= "font-size: 12.0pt; line-height: 115%;">@shikhajainmd</span></a><u><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">.</span></u> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> Gillaspie can be reached at</span> <a href= "mailto:eringillaspie@creighton.edu"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> eringillaspie@creighton.edu</span></a> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> or on Instagram</span> <a href= "https://www.instagram.com/dreringillaspie"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> @dreringillaspie</span></a><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">. Matt-Amaral can be reached at</span> <a href= "mailto:mattaml@ccf.org"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> mattaml@ccf.org</span></a><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">.</span></p> <p class="Disclosure">Jain reports no relevant financial disclosures. Gillaspie reports consulting or speakers bureau roles with and/or travel, accommodations and expenses from AstraZeneca, Bristol Myers Squibb, Genentech, Intuitive Surgical and Merck. Matt-Amaral reports research funding to her institution from Agendia.</p>
June 25, 2026
Breakthroughs in pancreatic cancer research, treatment spark excitement at ASCO
<p class="BodyCxSpFirst"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> In this episode,</span> <strong style= "mso-bidi-font-weight: normal;"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"> Shikha Jain, MD,</span></strong> <span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> speaks with Revolution Medicines'</span> <strong style= "mso-bidi-font-weight: normal;"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"> Alan Sandler, MD,</span></strong> <span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> about groundbreaking advancements with daraxonrasib and how these findings will continue to impact metastatic pancreatic cancer.</span></p> <p class="BodyCxSpMiddle"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> Daraxonrasib (RMC-6236, Revolution Medicines) is an investigational, oral pan-RAS inhibitor in development for treatment of advanced solid tumors, including pancreatic ductal adenocarcinoma.<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l1 level1 lfo2;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">Why the RASolute 302 trial got a standing ovation at ASCO. <strong>3:16<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l1 level1 lfo2;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">What do you think changed scientifically to make this particular drug and its results possible? <strong>6:12<br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l1 level1 lfo2;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">What does the multi-selective RAS inhibition of this drug mean, and how does it differ from other drugs?</span> <strong style= "mso-bidi-font-weight: normal;">10:23</strong><span style= "mso-bidi-font-weight: bold;"><br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l1 level1 lfo2;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">How would you recommend navigating the early access program (EAP) for patients and physicians who want this drug now? <strong>13:13<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l1 level1 lfo2;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->What excites you about the future of pancreatic cancer and RAS treatment? <strong>14:18<br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></p> <p class="BodyCxSpLast" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l1 level1 lfo2;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->How can you imagine when these drugs will get into the hands of patients if we see good results? <strong>17:28<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></p> <p class="HealioSubhead"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> We'd love to hear from you! Send your comments/questions to Jain at</span> <a href= "mailto:oncologyoverdrive@healio.com"><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> oncologyoverdrive@healio.com</span></a><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">. Follow Healio on X and LinkedIn:</span> <a href= "https://x.com/HemOncToday"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> @HemOncToday</span></a> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> and</span> <a href= "https://www.linkedin.com/company/hemonctoday/"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> https://www.linkedin.com/company/hemonctoday/</span></a><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">. Follow Jain on X:</span> <a href= "https://x.com/ShikhaJainMD"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> @ShikhaJainMD</span></a> <span style= "font-size: 12.0pt; line-height: 115%;">and on Instagram</span> <a href="https://www.instagram.com/shikhajainmd/"><span style= "font-size: 12.0pt; line-height: 115%;">@shikhajainmd</span></a><u><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">.</span></u> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> Sandler can be reached via email at</span> <a href= "mailto:inquiries@revmed.com"><span style= "font-size: 12.0pt; line-height: 115%;">inquiries@revmed.com</span></a><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">.</span></p> <p class="HealioSubhead">Reference:</p> <p class="Reference" style="mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Wolpin BM, et al. LBA5. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.</p> <p class="Disclosure">Jain and Sandler report no relevant financial disclosures.</p>
June 11, 2026
Live from ASCO 2026: Administrative roles, cultivating networks in cancer care
<p class="BodyCxSpFirst"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> In this episode, recorded live at ASCO Annual Meeting, host</span> <strong style="mso-bidi-font-weight: normal;"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"> Shikha Jain, MD,</span></strong> <span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> speaks with</span> <strong style= "mso-bidi-font-weight: normal;"><span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"> W. Kimryn Rathmell, MD, PhD,</span></strong> <span style= "mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-bidi-font-weight: bold;"> about the new and evolving ways cancer care is delivered, building networks through advocacy and more.<br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">Who is Dr. W. Kimryn Rathmell? <span style= "mso-spacerun: yes;"> </span><strong>2:17<br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">Jain and Rathmell discuss the need for physician scientists in administrative leadership. <strong>11:37<br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">How do you think networks and communities can impact careers?</span> <strong style= "mso-bidi-font-weight: normal;">17:08</strong><span style= "mso-bidi-font-weight: bold;"><br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><span style="mso-bidi-font-weight: bold;">What are your thoughts on using social media in the cancer space? <strong>22:35<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></span></p> <p class="BodyCxSpMiddle" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->How do you think AI is going to transform the way we deliver care? <strong>26:21<br style= "mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></p> <p class="BodyCxSpLast" style= "margin-left: 1.0in; mso-add-space: auto; text-indent: -.25in; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->As you have navigated your career, how have you approached challenges around being a woman in leadership roles? <strong>29:29<br style="mso-special-character: line-break;" /> <!-- [if !supportLineBreakNewLine]--><br style= "mso-special-character: line-break;" /> <!--[endif]--></strong></p> <p class="HealioSubhead"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> We'd love to hear from you! Send your comments/questions to Jain at</span> <a href= "mailto:oncologyoverdrive@healio.com"><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> oncologyoverdrive@healio.com</span></a><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">. Follow Healio on X and LinkedIn:</span> <a href= "https://twitter.com/HemOncToday"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> @HemOncToday</span></a> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> and</span> <a href= "https://www.linkedin.com/company/hemonctoday/"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> https://www.linkedin.com/company/hemonctoday/</span></a><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">. Follow Jain on X:</span> <a href= "https://twitter.com/ShikhaJainMD?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor"> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> @ShikhaJainMD</span></a> <span style= "font-size: 12.0pt; line-height: 115%;">and on Instagram</span> <a href="https://www.instagram.com/shikhajainmd/"><span style= "font-size: 12.0pt; line-height: 115%;">@shikhajainmd</span></a><u><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">.</span></u> <span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> Rathmell can be reached on</span> <a href= "https://www.linkedin.com/in/kimryn-rathmell/"><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';"> LinkedIn</span></a><span style= "font-size: 12.0pt; mso-bidi-font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">.</span></p> <p class="Disclosure">Jain reports no relevant financial disclosures. Rathmell reports a relationship with Interact Therapeutics, as well as institution relationships with Merck and Sitryx.</p>
138 total episodes available
Recent guests on Oncology Overdrive
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Mika Stambaugh
Guest
Elisabeth Potter MD
Guest
Don Dizon MD
Guest
Sonali Smith MD
Guest
Sadie Dobrozsi
Guest
Abiola Ibraheem MD
Guest
Nadine Spring PhD
Guest
Navin Goyal MD
Guest
Kimberly Richardson
Guest
Anna Rathkopf
Guest
Gwen L. Nichols, MD
Guest
Thomas G. Knight, MD
Guest
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Oncology Overdrive
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Oncology Overdrive?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.